Publication | Open Access

Ticagrelor versus Genotype-Driven Antiplatelet Therapy for Secondary Prevention after Acute Coronary Syndrome: A Cost-Effectiveness Analysis

ThrombosisCost-effectiveness AnalysisCardiovascular DiseaseBlood PlateletSecondary PreventionAcute Coronary SyndromeCardiologyPharmacotherapyAcute Myocardial InfarctionPlatelet AntagonistMedicineAnticoagulantAtherosclerosisEmergency MedicineCoronary Artery Disease